SlideShare ist ein Scribd-Unternehmen logo
1 von 81
Hypertension Physiology, Pathophysiology and Clinical Managements Jun  Tao
Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright  © 2002, with permission from Elsevier
Introduction ,[object Object]
[object Object]
[object Object]
Primary hypertension
Etiology and pathogenesis ,[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pathology ,[object Object]
Blood vessel change ,[object Object],[object Object]
[object Object]
 
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object]
Specific organ changes in hypertension ,[object Object],[object Object]
[object Object]
Hpertrophy of left ventricle
 
[object Object],[object Object]
[object Object]
 
 
[object Object],[object Object]
[object Object]
肾动脉硬化 肾动脉硬化 致密的肾盂 X 线影象
Malignant hypertension:  Fibrinoid necrosis of damaged arteriole of kidney
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Symptoms ,[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Symptoms associated with target organ damage ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Complications  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
physical examination  ,[object Object],[object Object],[object Object]
Diagnosis  ,[object Object]
 
CVD Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],*Components of the metabolic syndrome.
Cardiovascular risk category of hypertension   Blood pressure ( mmHg )   Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99)  Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk   Medium-risk High-risk   1 ~ 2  risk factors Moderate-risk   Medium-risk Very High-risk 3 or more  risk factors   , or diabetes , or target organ damage High-risk   High-risk   Very High-risk complications Very High-risk Very High-risk Very High-risk
Laboratory examinations ,[object Object],[object Object],[object Object]
Goals of Therapy ,[object Object],[object Object],[object Object]
Blood Pressure Reduction of 2 mmHg Decreases the Risk of Cardiovascular Events by 7–10% ,[object Object],[object Object],[object Object],2 mmHg decrease in mean SBP 10% reduction in risk of stroke mortality 7% reduction in risk of ischaemic heart disease mortality Lewington et al. Lancet 2002;360:1903–13
Lifestyle Modification ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg)  (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications  Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)  as needed.  With Compelling  Indications Stage 2 Hypertension   (SBP  > 160 or DBP  > 100 mmHg)  2-drug combination for most (usually thiazide-type diuretic and  ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg)  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB,  or combination. Without Compelling  Indications Not at Goal  Blood Pressure Optimize dosages or add additional drugs  until goal blood pressure is achieved. Consider consultation with hypertension specialist.
Drug treatment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],,
 
 
Classification and Management  of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg.  BP classification   SBP* mmHg   DBP* mmHg  Lifestyle modification   Initial drug therapy   Without compelling indication  With compelling indications Normal  <120  and <80  Encourage  Prehypertension  120–139  or 80–89  Yes  No antihypertensive drug indicated.  Drug(s) for compelling indications.  ‡   Stage 1 Hypertension  140–159  or 90–99  Yes  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB, or combination.  Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed.  Stage 2 Hypertension  > 160  or  > 100  Yes  Two-drug combination for most †  (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
 
 
Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged   50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration   3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
[object Object],[object Object],[object Object],[object Object],[object Object],Other medications for hypertensive patients
Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater Lipid targets
[object Object]
CVD Risk Factors ,[object Object],[object Object],[object Object]
Target organ damage ,[object Object],[object Object],[object Object],[object Object],[object Object]
ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients  with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
About drug treatment ,[object Object],[object Object],[object Object]
Screening and treatment of secondary forms of hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
谢谢!

Weitere ähnliche Inhalte

Was ist angesagt?

Mitral valve regurgitation
Mitral valve regurgitationMitral valve regurgitation
Mitral valve regurgitationMohammad Aladam
 
Ecg criteria of chamber enlargement
Ecg criteria of chamber enlargementEcg criteria of chamber enlargement
Ecg criteria of chamber enlargementAdarsh
 
Congestive heart failure
Congestive heart failure Congestive heart failure
Congestive heart failure Muhammadasif909
 
7.Valvular heart disease pathology
7.Valvular heart disease pathology7.Valvular heart disease pathology
7.Valvular heart disease pathologyPNK SINGH
 
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Bassel Ericsoussi, MD
 
Heart failure management
Heart failure managementHeart failure management
Heart failure managementHimanshu Jangid
 
Pulmonary Hypertension and its management
Pulmonary Hypertension and its managementPulmonary Hypertension and its management
Pulmonary Hypertension and its managementMohit Goyal
 
Valvular heart disease
Valvular heart diseaseValvular heart disease
Valvular heart diseasePuneet Shukla
 
Mitral stenosis (propeduetics)
Mitral stenosis (propeduetics)Mitral stenosis (propeduetics)
Mitral stenosis (propeduetics)ajith joseph
 
Diastolic Dysfunction 2016
Diastolic Dysfunction 2016Diastolic Dysfunction 2016
Diastolic Dysfunction 2016drabhishekbabbu
 
LEFT HEART CATHETERIZATION
LEFT HEART CATHETERIZATIONLEFT HEART CATHETERIZATION
LEFT HEART CATHETERIZATIONPraveen Nagula
 
Bradycardia Assessment and Management
Bradycardia Assessment and ManagementBradycardia Assessment and Management
Bradycardia Assessment and ManagementSCGH ED CME
 

Was ist angesagt? (20)

Mitral valve regurgitation
Mitral valve regurgitationMitral valve regurgitation
Mitral valve regurgitation
 
Ecg criteria of chamber enlargement
Ecg criteria of chamber enlargementEcg criteria of chamber enlargement
Ecg criteria of chamber enlargement
 
Congestive heart failure
Congestive heart failure Congestive heart failure
Congestive heart failure
 
7.Valvular heart disease pathology
7.Valvular heart disease pathology7.Valvular heart disease pathology
7.Valvular heart disease pathology
 
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
 
Heart failure management
Heart failure managementHeart failure management
Heart failure management
 
Right and left ventricular hypertrophy
Right and left ventricular hypertrophyRight and left ventricular hypertrophy
Right and left ventricular hypertrophy
 
Pulmonary Hypertension and its management
Pulmonary Hypertension and its managementPulmonary Hypertension and its management
Pulmonary Hypertension and its management
 
Aortic Regurgitation - Rivin
Aortic Regurgitation - RivinAortic Regurgitation - Rivin
Aortic Regurgitation - Rivin
 
Heart Failure
Heart FailureHeart Failure
Heart Failure
 
Ecg fundamentals
Ecg fundamentalsEcg fundamentals
Ecg fundamentals
 
Valvular heart disease
Valvular heart diseaseValvular heart disease
Valvular heart disease
 
Lvh
LvhLvh
Lvh
 
Hypertension Guide Lines for 2020
Hypertension Guide Lines for 2020Hypertension Guide Lines for 2020
Hypertension Guide Lines for 2020
 
Mitral stenosis (propeduetics)
Mitral stenosis (propeduetics)Mitral stenosis (propeduetics)
Mitral stenosis (propeduetics)
 
Diastolic Dysfunction 2016
Diastolic Dysfunction 2016Diastolic Dysfunction 2016
Diastolic Dysfunction 2016
 
LEFT HEART CATHETERIZATION
LEFT HEART CATHETERIZATIONLEFT HEART CATHETERIZATION
LEFT HEART CATHETERIZATION
 
Bradycardia Assessment and Management
Bradycardia Assessment and ManagementBradycardia Assessment and Management
Bradycardia Assessment and Management
 
Heart Failure
Heart FailureHeart Failure
Heart Failure
 
Lvh &amp; rvh
Lvh &amp; rvhLvh &amp; rvh
Lvh &amp; rvh
 

Andere mochten auch

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathyfitango
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureayeayetun08
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.pptShama
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.pptShama
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases pptUma Binoy
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASEhanisahwarrior
 

Andere mochten auch (12)

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failure
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku joseph
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.ppt
 
Heart Disease
Heart DiseaseHeart Disease
Heart Disease
 
Valvular heart disease and anaesthesia
Valvular heart disease and anaesthesiaValvular heart disease and anaesthesia
Valvular heart disease and anaesthesia
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases ppt
 
Heart disease
Heart disease Heart disease
Heart disease
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 

Ähnlich wie 10 hypertension (20)

HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSION
 
1. Hypertension (2).pptx
1. Hypertension (2).pptx1. Hypertension (2).pptx
1. Hypertension (2).pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension (htn)
Hypertension (htn)Hypertension (htn)
Hypertension (htn)
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
HYPERTENSION (4).ppt
HYPERTENSION (4).pptHYPERTENSION (4).ppt
HYPERTENSION (4).ppt
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Mgt of htn crisis by gelaye
Mgt of htn crisis  by gelayeMgt of htn crisis  by gelaye
Mgt of htn crisis by gelaye
 
hypertension.docx
hypertension.docxhypertension.docx
hypertension.docx
 

Mehr von internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeinternalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhouinternalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal diseaseinternalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitisinternalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitisinternalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathyinternalmed
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial diseaseinternalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gaointernalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 

Mehr von internalmed (20)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 

Kürzlich hochgeladen

Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
Choosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for ParentsChoosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for Parentsnavabharathschool99
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYKayeClaireEstoconing
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17Celine George
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Seán Kennedy
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood
 
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxPoojaSen20
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinojohnmickonozaleda
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxMaryGraceBautista27
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfTechSoup
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 

Kürzlich hochgeladen (20)

Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
Choosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for ParentsChoosing the Right CBSE School A Comprehensive Guide for Parents
Choosing the Right CBSE School A Comprehensive Guide for Parents
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
 
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
 
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxYOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipino
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptx
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 

10 hypertension

  • 1. Hypertension Physiology, Pathophysiology and Clinical Managements Jun Tao
  • 2. Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright © 2002, with permission from Elsevier
  • 3.
  • 4.
  • 5.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.  
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26. Hpertrophy of left ventricle
  • 27.  
  • 28.
  • 29.
  • 30.  
  • 31.  
  • 32.
  • 33.
  • 35. Malignant hypertension: Fibrinoid necrosis of damaged arteriole of kidney
  • 36.
  • 37.  
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.  
  • 51.
  • 52. Cardiovascular risk category of hypertension   Blood pressure ( mmHg ) Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99) Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk Medium-risk High-risk 1 ~ 2 risk factors Moderate-risk Medium-risk Very High-risk 3 or more risk factors , or diabetes , or target organ damage High-risk High-risk Very High-risk complications Very High-risk Very High-risk Very High-risk
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59. Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. With Compelling Indications Stage 2 Hypertension (SBP > 160 or DBP > 100 mmHg) 2-drug combination for most (usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Without Compelling Indications Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.  
  • 68.  
  • 69. Classification and Management of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg. BP classification SBP* mmHg DBP* mmHg Lifestyle modification Initial drug therapy Without compelling indication With compelling indications Normal <120 and <80 Encourage Prehypertension 120–139 or 80–89 Yes No antihypertensive drug indicated. Drug(s) for compelling indications. ‡ Stage 1 Hypertension 140–159 or 90–99 Yes Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Stage 2 Hypertension > 160 or > 100 Yes Two-drug combination for most † (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
  • 70.  
  • 71.  
  • 72. Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged  50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration  3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
  • 73.
  • 74. Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater Lipid targets
  • 75.
  • 76.
  • 77.
  • 78. ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
  • 79.
  • 80.

Hinweis der Redaktion

  1. These data are taken from a meta-analysis of 61 prospective observational studies on deaths from vascular disease among subjects without vascular disease at baseline. The results demonstrated that the relationship of stroke mortality (left panel) and ischemic heart disease (IHD) mortality (right panel) to usual BP is strong and direct at all ages. As highlighted on the following slide, each difference of 20 mmHg in usual systolic BP is associated with a two-fold difference in the risk of stroke mortality and IHD mortality (between ages 40–69 years). The annual absolute difference in risk is greater in old age. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  2. Trials have shown that BP lowering can produce rapid reductions in cardiovascular disease risk. In fact, even a 2 mmHg decrease in systolic BP would result in approximately 7% lower mortality risk from ischemic heart disease and a 10% lower mortality risk from stroke. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  3. bhs guidelines 2004.boeh-ingel
  4. bhs guidelines 2004.boeh-ingel
  5. bhs guidelines 2004.boeh-ingel
  6. bhs guidelines 2004.boeh-ingel
  7. bhs guidelines 2004.boeh-ingel